Peptron, Inc.
Founded in 1997 and KOSDAQ-listed in 2015, Peptron develops peptide-based sustained-release drugs and novel drug candidates.
As of 2026-10-10, Peptron, Inc. has 1 Korean MFDS drug approval, 22 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 1997 and listed on KOSDAQ in 2015, Peptron is a peptide sustained-release drug company. Based on peptide engineering and sustained-release technology, it designs and manufactures long-acting smart drugs and peptide new drugs, and operates GMP mass-production facilities that contract-manufacture PRESENDIN, an idiopathic intracranial hypertension (IIH) treatment, for Invex Therapeutics of Australia. In 2014 Peptron licensed in worldwide exclusive rights to a GLP-1 analog-based neurodegenerative disease treatment from the US National Institutes of Health (NIH) and completed a Phase 2 trial for Parkinson's disease in Korea, and in 2021 it signed a contract manufacturing agreement with Invex Therapeutics covering the ten years following commercial launch.
Regulatory approvals
data.go.kr1 Korean MFDS drug approvals · 2025
- MFDS drugLEUPONE Inj. 3.75mg2025-07-15Drug · Prescription · Approval202501787
Clinical trials
data.go.kr3 MFDS clinical trial authorisations · 2015–2022 (Bioequivalence 2 · Phase 2a 1)
- BioequivalencePT1052022-02-15
2 trial sites
- BioequivalencePT1052021-01-14
2 trial sites
- Phase 2aPT3202015-01-12
5 trial sites
Global clinical trials
ClinicalTrials.gov · sponsor-matchedPhase 1 · Unknown · 2021-03 · NCT04783636
Phase 2 · Unknown · 2020-03 · NCT04269642
Phase 1 · Completed · 2009-08 · NCT00964262
R&D and key agreements
Source: DART corporate disclosure퇴행성신경질환 치료제(GLP-1 유사체) · 파킨슨병 · 임상 2상(국내) 종료 · GLP-1 analog-based neurodegenerative disease treatment licensed in from the US NIH under a worldwide exclusive license, contract signed 2014-05-29
Key disclosures
KRX KIND via OpenDARTPublications
PubMed · affiliation-matched- PT320, a GLP-1 receptor agonist, mitigates nucleus accumbens-associated depression- and anxiety-like behaviors in MitoPark mice of Parkinson's disease.
Journal of Parkinson's disease · 2026-08 · Tseng KY, Kuo TT, Chang PK 외 7
- Corrigendum to "Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury" [Neurobiology of Disease Volume 124 (2019) 439-453 /YNBDI_4338].
Neurobiology of disease · 2024-09 · Bader M, Li Y, Lecca D 외 10
- Attenuating mitochondrial dysfunction and morphological disruption with PT320 delays dopamine degeneration in MitoPark mice.
Journal of biomedical science · 2024-04 · Wang V, Tseng KY, Kuo TT 외 10
- PT320, a Sustained-Release GLP-1 Receptor Agonist, Ameliorates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson's Disease.
International journal of molecular sciences · 2023-02 · Kuo TT, Chen YH, Wang V 외 8
- IVIVC of Octreotide in PLGA-Glucose Microsphere Formulation, Sandostatin® LAR.
AAPS PharmSciTech · 2022-09 · Song JS, Kim SY, Nam JH 외 3
- Sustained Release GLP-1 Agonist PT320 Delays Disease Progression in a Mouse Model of Parkinson's Disease.
ACS pharmacology & translational science · 2021-04 · Wang V, Kuo TT, Huang EY 외 12
- PT320, Sustained-Release Exendin-4, Mitigates L-DOPA-Induced Dyskinesia in a Rat 6-Hydroxydopamine Model of Parkinson's Disease.
Frontiers in neuroscience · 2020-01 · Yu SJ, Chen S, Yang YY 외 8
- Pharmacokinetics of Exenatide in nonhuman primates following its administration in the form of sustained-release PT320 and Bydureon.
Scientific reports · 2019-11 · Li Y, Vaughan KL, Tweedie D 외 6
- Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury.
Neurobiology of disease · 2019-04 · Bader M, Li Y, Lecca D 외 10
- Author Correction: Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson's disease.
Scientific reports · 2018-09 · Chen S, Yu SJ, Li Y 외 8
Show 12 more publications
- Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson's disease.
Scientific reports · 2018-07 · Chen S, Yu SJ, Li Y 외 8
- A Novel Monoclonal Antibody Targets Mucin1 and Attenuates Growth in Pancreatic Cancer Model.
International journal of molecular sciences · 2018-07 · Wu G, Maharjan S, Kim D 외 6
- A Mucin1 C-terminal Subunit-directed Monoclonal Antibody Targets Overexpressed Mucin1 in Breast Cancer.
Theranostics · 2018-01 · Wu G, Kim D, Kim JN 외 6
- A New Treatment Strategy for Parkinson's Disease through the Gut-Brain Axis: The Glucagon-Like Peptide-1 Receptor Pathway.
Cell transplantation · 2017-09 · Kim DS, Choi HI, Wang Y 외 3
- Exendin-4 attenuates blast traumatic brain injury induced cognitive impairments, losses of synaptophysin and in vitro TBI-induced hippocampal cellular degeneration.
Scientific reports · 2017-06 · Rachmany L, Tweedie D, Rubovitch V 외 9
- Synergistic inhibition effect of TNIK inhibitor KY-05009 and receptor tyrosine kinase inhibitor dovitinib on IL-6-induced proliferation and Wnt signaling pathway in human multiple myeloma cells.
Oncotarget · 2017-06 · Lee Y, Jung JI, Park KY 외 2
- Prevention and treatment effect of evogliptin on hepatic steatosis in high-fat-fed animal models.
Archives of pharmacal research · 2017-02 · Kim MK, Chae YN, Ahn GJ 외 5
- Mild traumatic brain injury-induced hippocampal gene expressions: The identification of target cellular processes for drug development.
Journal of neuroscience methods · 2016-10 · Tweedie D, Rachmany L, Kim DS 외 7
- Peptide Immunotherapy in Vaccine Development: From Epitope to Adjuvant.
Advances in protein chemistry and structural biology · 2015-01 · Yang H, Kim DS
- Pharmacokinetic properties and effects of PT302 after repeated oral glucose loading tests in a dose-escalating study.
Clinical therapeutics · 2014-01 · Gu N, Cho SH, Kim J 외 7
- Cancer vaccines in the immunotherapy era: rational approach.
Human vaccines & immunotherapeutics · 2013-09 · Kim DS
- Design and efficient synthesis of novel ascorbyl conjugated peptide with high collagen biosynthesis stimulating effects.
Bioorganic & medicinal chemistry letters · 2009-04 · Choi HI, Kim HJ, Park JI 외 3
Patents
KIPRIS · applicant-matchedPublished · 2026-03 · Application 1020260047862
Published · 2024-12 · Application 1020240193358
PCT · Published · 2024-12 · Application PCT/KR2024/097131
PCT · Published · 2024-11 · Application PCT/KR2024/017916
Published · 2023-12 · Application 1020230189038
EP · Published · 2023-12 · Application 23904081.9
PCT · Published · 2023-12 · Application PCT/KR2023/020910
Registered · 2023-12 · Application 1020230184732
Published · 2023-11 · Application 1020230159452
US · Published · 2022-08 · Application 18686834
Show 98 more patents
EP · Published · 2022-08 · Application 22861742.9
PCT · Published · 2022-08 · Application PCT/KR2022/012764
Published · 2022-08 · Application 1020220106864
US · Registered · 2022-07 · Application 17811904
US · Registered · 2022-07 · Application 17811845
EP · Published · 2022-06 · Application 22828803.1
US · Published · 2022-06 · Application 18565190
PCT · Published · 2022-06 · Application PCT/KR2022/008984
Registered · 2022-06 · Application 1020220077146
US · Registered · 2021-11 · Application 17522687
US · Registered · 2020-12 · Application 17116265
EP · Registered · 2020-07 · Application 20846757.1
US · Registered · 2020-07 · Application 17630799
PCT · Published · 2020-07 · Application PCT/KR2020/010023
Registered · 2020-07 · Application 1020200094783
Registered · 2020-06 · Application 1020200075680
CN · Published · 2018-03 · Application 201880026127.7
EP · Published · 2018-03 · Application 20212863.3
EP · Published · 2018-03 · Application 18771928.1
US · Registered · 2018-03 · Application 16495373
PCT · Published · 2018-03 · Application PCT/KR2018/003267
Registered · 2018-03 · Application 1020180032592
CN · Published · 2017-10 · Application 201780078697.6
EP · Published · 2017-10 · Application 25181393.7
EP · Published · 2017-10 · Application 17800650.8
US · Registered · 2017-10 · Application 16342685
PCT · Published · 2017-10 · Application PCT/US2017/057606
Rejected · 2017-10 · Application 1020197014421
Registered · 2017-10 · Application 1020217022385
Withdrawn · 2017-08 · Application 1020170107148
PCT · Published · 2016-11 · Application PCT/KR2016/013033
PCT · Published · 2016-11 · Application PCT/KR2016/013031
Registered · 2016-11 · Application 1020160149948
Registered · 2016-11 · Application 1020160149947
Registered · 2015-10 · Application 1020150152415
Registered · 2015-10 · Application 1020150152414
Registered · 2014-12 · Application 1020140170449
Registered · 2014-12 · Application 1020140170459
CN · Published · 2014-08 · Application 201480044736
CN · Published · 2014-08 · Application 201480044684.3
EP · Registered · 2014-08 · Application 14853508.1
EP · Registered · 2014-08 · Application 14854358.0
US · Registered · 2014-08 · Application 15029604
US · Registered · 2014-08 · Application 15029612
PCT · Published · 2014-08 · Application PCT/KR2014/007658
PCT · Published · 2014-08 · Application PCT/KR2014/007656
Registered · 2013-10 · Application 1020130124102
Registered · 2013-10 · Application 1020130124096
Registered · 2011-09 · Application 1020110098707
Registered · 2008-01 · Application 1020080009066
Registered · 2008-01 · Application 1020080009108
EP · Registered · 2008-01 · Application 08712168.7
PCT · Published · 2008-01 · Application PCT/KR2008/000397
Expired · 2007-11 · Application 1020070123030
CN · Published · 2007-05 · Application 200780019612
EP · Registered · 2007-05 · Application 07746488.1
PCT · Published · 2007-05 · Application PCT/KR2007/002339
Registered · 2007-03 · Application 1020070029586
EP · Published · 2006-10 · Application 06812267.0
US · Published · 2006-10 · Application 12090969
PCT · Published · 2006-10 · Application PCT/KR2006/004428
PCT · Published · 2006-10 · Application PCT/KR2006/004427
Expired · 2006-10 · Application 1020087009798
Withdrawn · 2006-10 · Application 1020087009799
EP · Registered · 2006-09 · Application 06783775.7
PCT · Published · 2006-09 · Application PCT/KR2006/003520
US · Published · 2006-08 · Application 11511951
Registered · 2006-06 · Application 1020060056580
Registered · 2006-06 · Application 1020060054174
Registered · 2006-05 · Application 1020060042462
Expired · 2006-01 · Application 1020060002888
PCT · Published · 2005-04 · Application PCT/KR2005/001111
EP · Published · 2004-09 · Application 04774502.1
PCT · Published · 2004-09 · Application PCT/KR2004/002241
EP · Registered · 2004-06 · Application 04748351.6
PCT · Published · 2004-06 · Application PCT/KR2004/001558
Expired · 2004-04 · Application 1020040027275
Expired · 2004-03 · Application 1020040018506
Expired · 2003-09 · Application 1020030061943
Expired · 2003-07 · Application 1020030047300
Expired · 2003-07 · Application 1020030046717
Expired · 2003-06 · Application 1020030042249
US · Published · 2003-05 · Application 10512090
PCT · Published · 2003-05 · Application PCT/KR2003/000921
Expired · 2003-05 · Application 1020030029407
Expired · 2003-04 · Application 1020030023130
Expired · 2002-10 · Application 1020020065072
PCT · Published · 2002-05 · Application PCT/KR2002/000948
Expired · 2001-07 · Application 1020010043001
EP · Published · 2001-03 · Application 01917893.8
PCT · Published · 2001-03 · Application PCT/KR2001/000462
PCT · Published · 2001-02 · Application PCT/KR2001/000232
PCT · Published · 2000-09 · Application PCT/KR2000/001095
Expired · 2000-09 · Application 1020000057197
Expired · 2000-08 · Application 1020000049344
Expired · 2000-03 · Application 1020000016267
Expired · 2000-01 · Application 1020000000706
Expired · 1999-06 · Application 1019990023397
AI reads
MAA server logs · IP-verifiedPulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.
Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.
Collected as raw material for future answers.
Queries from users who connected this index to their own AI.
- OpenAIChatGPT-Userlive5
- OpenAIOAI-SearchBot74
- PerplexityPerplexityBot6
- GoogleGoogleOther2
- AnthropicClaudeBot2
- MicrosoftBingbot1
Measured since Aug 27, 2026 · 5 AI engines · last read Oct 9, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.
Connect this company index directly to your AI
Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for Peptron, Inc. and every listed Korean medical, bio and AI company.
How to connect (MCP)Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Drug delivery system company behind the long-acting injectable platform IVL-DrugFluidic and the LNP delivery platform IVL-GeneFluidic.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
A holding company overseeing 54 affiliates including its main biopharmaceutical subsidiary GC, with no direct product manufacturing of its own.
Founded in 2015 and listed on KOSPI in 2021, Prestige BioPharma develops antibody biosimilars and novel antibody drugs including Tuznue.
KOSDAQ-listed biotech company developing molecular diagnostics with proprietary C-Tag technology and the NeoPlex product line.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
Sources and updates
Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- Approvals & clinical trials
- Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
- Key disclosures
- KRX KIND via OpenDART exchange filings — updated daily
- Global clinical trials
- ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
- Financials
- DART corporate disclosure filings — annual
- Publications
- PubMed (US National Library of Medicine) — affiliation-matched, updated daily
- Patents
- KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
- AI reads
- Our server logs, IP-verified every 6 hours
- AI visibility
- Measured 2026-10-01
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition